EUVIMEDEUVIMED entdecken
Crossref

COVID-19 Infection in Patients with Follicular Lymphoma and Related Indolent B-Cell Lymphomas Receiving Anti-CD20 Monoclonal Antibody Maintenance Therapy

Shinto Kuniyoshi, Kohei Tanaka, Yu Akuzawa, Shunsuke Homma, Miyuki Okura, Takamitsu Okamura, Toru Kiguchi, Hiroki Sugimori, Koshi Hashimoto, Hideto Tamura

Acta Haematologica · 08.06.2026 · 1-10

DOI: 10.1159/000552825 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Haematologica, online erschienen am 08.06.2026. Verfasst von Shinto Kuniyoshi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Diabetes, Endocrinology and Hematology, Department of Internal Medicine, Dokkyo Medical University Saitama Medical Center, Saitama, Japan. Die Arbeit nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Coronavirus disease 2019 (COVID-19) poses significant risks to immunocompromised individuals. Patients receiving maintenance therapy with anti-CD20 monoclonal antibodies for follicular lymphoma (FL) may be especially vulnerable because of prolonged B-cell depletion. However, data from Japan, particularly from the later stages of the pandemic, remain limited. This study aimed to investigate the incidence, severity, duration, mortality, and treatment discontinuation associated with COVID-19 in this population.

Methods

We retrospectively analyzed all consecutive 72 patients with FL or related indolent B-cell lymphomas, including transformed FL, who received anti-CD20 maintenance therapy (rituximab or obinutuzumab) at our institute between January 2020 and September 2023. All patients had an indolent lymphoma background. Data on clinical features, laboratory values, disease severity at initial diagnosis according to Ministry of Health, Labour and Welfare guidelines, hospitalization, outcomes, duration of polymerase chain reaction positivity (>21 days defined as prolonged), and maintenance therapy continuation were reviewed. Fisher’s exact test was used for analysis.

Results

Among the 72 patients (median age: 69 years), 16 (22.2%) developed COVID-19. Of these, 5 had received rituximab and 11 obinutuzumab. The median lymphocyte count at infection was 498/μL; no patient had serum IgG

Schlagwörter

Stichwörter der Autor:innen

Anti-CD20 monoclonal antibodyCOVID-19LymphomaObinutuzumabSARS-CoV-2

Autor:innen und Institutionen

  • Division of Diabetes, Endocrinology and Hematology, Department of Internal Medicine, Dokkyo Medical University Saitama Medical Center, Saitama, Japan.
  • Department of Hematology, Nippon Medical School, Tokyo, Japan.
  • Department of Preventive Medicine, Daito Bunka University Graduate School of Sports and Health Science, Saitama, Japan.
  • Division of Diabetes, Endocrinology and Hematology, Department of Internal Medicine, Dokkyo Medical University Saitama Medical Center, Saitama, Japan, tamh@dokkyomed.ac.jp.

Zitieren

APA

Kuniyoshi, S., Tanaka, K., Akuzawa, Y., Homma, S., Okura, M., Okamura, T., Kiguchi, T., Sugimori, H., Hashimoto, K., & Tamura, H. (2026). COVID-19 Infection in Patients with Follicular Lymphoma and Related Indolent B-Cell Lymphomas Receiving Anti-CD20 Monoclonal Antibody Maintenance Therapy. Acta Haematologica, 1-10. https://doi.org/10.1159/000552825

Vancouver

Kuniyoshi S, Tanaka K, Akuzawa Y, Homma S, Okura M, Okamura T, et al. COVID-19 Infection in Patients with Follicular Lymphoma and Related Indolent B-Cell Lymphomas Receiving Anti-CD20 Monoclonal Antibody Maintenance Therapy. Acta Haematologica. 2026:1-10. doi:10.1159/000552825

BibTeX
@article{Kuniyoshi2026,
  author = {Kuniyoshi, Shinto and Tanaka, Kohei and Akuzawa, Yu and Homma, Shunsuke and Okura, Miyuki and Okamura, Takamitsu and Kiguchi, Toru and Sugimori, Hiroki and Hashimoto, Koshi and Tamura, Hideto},
  title = {COVID-19 Infection in Patients with Follicular Lymphoma and Related Indolent B-Cell Lymphomas Receiving Anti-CD20 Monoclonal Antibody Maintenance Therapy},
  journal = {Acta Haematologica},
  year = {2026},
  pages = {1--10},
  doi = {10.1159/000552825}
}
Kostenlos starten →